Clinical Trials Browser

Phase 1/2 × Rectal Neoplasms × sintilimab × Clear all

NCT04636008 2024-08-06

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Turcot syndrome, Rectal Neoplasms